Compounded with
Semaglutide
Not verified in the bound record.
Tirzepatide
Not verified in the bound record.
Product evidence does not establish current availability.
Pharmacy evidence record · researched 2026-08-20
FarmaKeio Pharmacy Network
FarmaKeio network entities include Farmakeio Outsourcing LLC and North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
8 citations3 action records6 explicit unknowns
Locations in the source record
- 920 S Kimball Ave, Suite 100, Southlake, TX 76092-9019
- 1736 North Greenville Avenue, Richardson, TX 75081-1808
Services named by sources
- 503A patient-specific custom compounding
- 503B outsourcing
- Sterile compounded products
- Weight-management compounding
Regulatory compliance
503 pathway evidence
A pathway label describes which federal rules apply — it is not a quality claim.
Section 503A
Source-backed pathway evidence
FDA's action index labels this exact network entity a 503A facility. Section 503A is statutory and is not FDA facility registration.
Section 503B
Source-backed pathway evidence
FDA's action index labels the exact Southlake entity a 503B facility, and an FDA warning letter documents registration as an outsourcing facility. The most recent weekly registry row/date was not recovered.
Telehealth providers
No provider relationship is verified in the bound sources.
Clinic Scout links a provider only when an explicit source names the relationship.
Regulatory history
Actions stay dated and bounded.
FDA warning-letter, closeout, Form 483, compounding-action and current-registry sources were checked. State-board action searches were not exhaustive.
U.S. Food and Drug Administration · 2021-07-29
Warning Letter
FDA stated that products failed to meet all conditions of section 503B and cited unapproved and misbranded drug-product violations.
issued_current_closeout_unverifiedU.S. Food and Drug Administration · 2022-11-18
Warning Letter
FDA cited serious sterile-production deficiencies and insanitary conditions; FDA later stated that the firm appeared to have adequately addressed the warning-letter violations.
closed_out_2026-01-27U.S. Food and Drug Administration · 2025-09-05
Form FDA 483
FDA listed five inspection observations concerning investigations, laboratory controls, release testing, equipment qualification and calibration. A Form 483 records inspectional observations and is not a final agency determination.
issuedWhat remains unverified
- Founded year
- Explicit semaglutide relevance
- Explicit tirzepatide relevance
- Current weekly 503B registration date
- Full state-board license verification
- State-board disciplinary actions
Patient reviews
Share your experience for moderationNo Clinic Scout patient reviews are published for this pharmacy. Submissions go through manual moderation before anything appears here.
What this record verifies for you
6 evidence dimensions carry dated, source-backed verification.
Each line traces to a citation in the source list below — read the exact captured wording before relying on it.
- dated source ledger: 8 first-party/regulator citations with URL, accessed date, and exact supporting quote.
- legal entity provenance: Legal entity recorded as FarmaKeio network entities include Farmakeio Outsourcing LLC and North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding with status verified_fda_entities.
- regulator verified state evidence: 1 regulator-verified state record(s) preserved with field-level provenance.
- regulatory action timeline: 3 dated regulatory/action record(s) with bounded summaries and regulator citations.
- 503 status provenance: 503A/503B fields preserve pathway, source status, and current-versus-historical limits from the bound research.
- transparent unknowns: 6 unresolved field(s) are explicitly named and prevented from rendering as facts.
No superiority claim is made for review volume, ratings, or patient sentiment.
Sources and exact captured wording
- first_party · accessed 2026-08-20
Discover a 503B pharmaceutical outsourcing facility dedicated to the achievement of the highest standards in the industry.
- first_party · accessed 2026-08-20
FarmaKeio Custom Compounding is licensed in the following states:
- fda · accessed 2026-08-20
Farmakeio Outsourcing LLC, Southlake, TX - 503B Facility
- fda · accessed 2026-08-20
North American Custom Laboratories, LLC (dba FarmaKeio Superior Custom Compounding), Richardson, TX – 503A Facility
- fda · accessed 2026-08-20
You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act
- fda · accessed 2026-08-20
During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.
- fda · accessed 2026-08-20
Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
- fda · accessed 2026-08-20
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance.
Questions readers ask
Is FarmaKeio Pharmacy Network legit?
GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 8 dated first-party or regulator citation(s), 3 regulatory/action record(s), and 6 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.